论文部分内容阅读
目的:评价DC-CIK细胞治疗晚期转移性鼻咽癌患者的疗效。方法:回顾性分析2011年8月至2015年6月解放军第八一医院肿瘤生物治疗科行DC-CIK细胞治疗的29例晚期转移性鼻咽癌患者。观察DC-CIK细胞治疗前后患者的疗效、安全性及EB病毒VCA-IgA抗体水平和淋巴细胞亚群的变化。结果:29例鼻咽癌患者经DC-CIK细胞治疗后客观缓解率为0,疾病控制率为65.5%,中位生存时间为42个月,1~4年生存率都为68.0%,无严重不良反应。治疗后29例患者的外周血EB病毒VCA-IgA抗体显著低于治疗前[(30.88±3.91)U/ml vs(49.86±5.02)U/ml,P<0.05)]。经细胞治疗后CD8~+T细胞显著上升(P<0.05)、CD4~+/CD8~+T细胞比值显著下降(P<0.05)。结论:DC-CIK细胞治疗转移性鼻咽癌安全、可行,能产生一定的临床获益。
Objective: To evaluate the efficacy of DC-CIK cells in the treatment of patients with advanced metastatic nasopharyngeal carcinoma. Methods: A retrospective analysis of 29 patients with advanced metastatic nasopharyngeal carcinoma treated with DC-CIK cells from the Department of Tumor Biotherapy, the 81st Hospital of PLA from August 2011 to June 2015 was retrospectively analyzed. To observe the curative effect and safety of patients with DC-CIK cells before and after treatment and the changes of VCA-IgA antibody level and lymphocyte subsets of Epstein-Barr virus. Results: The objective response rate was 65.5% in patients with nasopharyngeal carcinoma treated by DC-CIK cells, the median survival time was 42 months, and the survival rates in 1 ~ 4 years were 68.0% Adverse reactions. After treatment, the peripheral blood Epstein-Barr virus VCA-IgA antibodies in 29 patients were significantly lower than those before treatment [(30.88 ± 3.91) U / ml vs (49.86 ± 5.02) U / ml, P <0.05). The percentage of CD4 ~ + / CD8 ~ + T cells was significantly decreased (P <0.05) after treatment with CD8 + T cells. Conclusion: DC-CIK cells in the treatment of metastatic nasopharyngeal carcinoma is safe and feasible, and can produce some clinical benefits.